Meeting the NSF targets for door-to-needle time in acute myocardial infarction - The role of a bolus thrombolytic

British Journal of Cardiology

Volumn 13, Issue 1, 2006, Pages 36-41

  Kuppuswamy, Velmurugan C ^a   Webbe, Daniela ^a   Gupta, Sandeep ^a  

^a WHIPPS CROSS UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Bolus Thrombolytic; Reteplase; Thrombolysis; Tissue plasminogen activator

Indexed keywords

RETEPLASE; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; ARTICLE; BLOOD CLOT LYSIS; BOLUS INJECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EMERGENCY WARD; FIBRINOLYTIC THERAPY; HOSPITAL CARE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL AUDIT; NEEDLE; PROSPECTIVE STUDY;

EID: 33644614946     PISSN: 09696113     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. British Heart Foundation. Coronary heart disease statistics. London: British Heart Foundation, 2004.
2. Chambless L, Keil U, Dobson A et al. for the WHO MONICA Project. Population versus clinical view of case fatality from acute coronary heart disease: results from the WHO MONICA Project 1985-1990. Circulation 1997;96:3849-59.
3. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;ii:349-60.
4. AIMS Trial Study Group. Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo-controlled clinical trial. Lancet 1988;i:545-9.
5. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994;343:311-22.
6. Boersma E, Maas ACP, Deckers JW et al. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet 1996;348:771-5.
7. Birkhead JS, on behalf of the joint audit committee of the British Cardiac Society and a cardiology committee of Royal College of Physicians of London. Time delays in provision of thrombolytic treatment in six district hospitals. BMJ 1992;305:445-8.
8. Hood S, Birnie D, Swan L et al. Questionnaire survey of thrombolytic treatment in accident and emergency departments in the United Kingdom. BMJ 1998;316:274.
9. Department of Health. National Service Framework for Coronary Heart Disease (Modern standards and service models). London: Department of Health, 2000.
10. GREAT Group. Feasibility, safety; and efficacy of domiciliary thrombolysis by general practitioners: Grampian Region Early Anistreplase Trial. BMJ 1992;305:548-53.
11. Gupta S. Pre-hospital thrombolysis in acute MI: has its time come? Cardiology News 2003;6:6-9.
12. Flisher D. Fast track: early thrombolysis. Br J Nurs 1995;4:562-5.
13. Hourigan CT, Mountain D, Langton PE et al. Changing the site of delivery of thrombolytic treatment for acute myocardial infarction from the coronary care unit to the emergency department greatly reduces door to needle time. Heart 2000;84:157-63.
14. Hughes C, Scott K, Saltissi S et al. The effect of an acute chest pain nurse (ACPN) on door to needle times at an inner city teaching hospital. Heart 1997;77(suppl 1):49.
15. Wilmshurst P, Purchase A, Webb C et al. Improving door to needle times with nurse initiated thrombolysis. Heart 2000;84:262-6.
16. Mooraby A, Rowe R, Walsh F et al. Closing the audit loop: nurse led thrombolytic therapy Heart 1997;77(suppl 1):192.
17. Caunt J. The advanced nurse practitioner in CCU. Care of the Critically III 1996;12:136-9.
18. Quinn T. Can nurses safely assess suitability for thrombolytic therapy? A pilot study. Intens Crit Care Nurs 1995;11:126-9.
19. Leah V, Clark C, Doyle K, Coats TJ. Does a single bolus thrombolytic reduce door to needle time in a district general hospital? Emerg Med J 2004;21:162-4.